Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
September 07, 2023 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
August 14, 2023 16:00 ET
|
Achieve Life Sciences
Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE and VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:...
Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast
August 01, 2023 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global...
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
May 25, 2023 09:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
May 23, 2023 06:00 ET
|
Achieve Life Sciences
ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo ...